These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23540741)

  • 21. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
    Albini A; Pennesi G; Donatelli F; Cammarota R; De Flora S; Noonan DM
    J Natl Cancer Inst; 2010 Jan; 102(1):14-25. PubMed ID: 20007921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted cancer therapeutics: the heartbreak of success.
    Mann DL
    Nat Med; 2006 Aug; 12(8):881-2. PubMed ID: 16892027
    [No Abstract]   [Full Text] [Related]  

  • 23. [Early detection of cardiotoxicity of anthracyclines. Value of isotopic method].
    Massing JL; Caillot D; Mouhat T; Schlesser P; Solary E
    Arch Mal Coeur Vaiss; 1996 Jan; 89(1):57-62. PubMed ID: 8678739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental animal model for anthracycline-induced heart failure.
    Perik PJ; van den Berg MP; de Vries EG; van Veldhuisen DJ
    Eur J Heart Fail; 2004 Jun; 6(4):375-6. PubMed ID: 15182760
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
    Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S55-63. PubMed ID: 27183526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer drugs and the heart: importance and management.
    Suter TM; Ewer MS
    Eur Heart J; 2013 Apr; 34(15):1102-11. PubMed ID: 22789916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents.
    Chen C; Heusch A; Donner B; Janssen G; Göbel U; Schmidt KG
    Klin Padiatr; 2009; 221(3):162-6. PubMed ID: 19437364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies.
    Adão R; de Keulenaer G; Leite-Moreira A; Brás-Silva C
    Rev Port Cardiol; 2013 May; 32(5):395-409. PubMed ID: 23623503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge.
    Tocchetti CG; Ragone G; Coppola C; Rea D; Piscopo G; Scala S; De Lorenzo C; Iaffaioli RV; Arra C; Maurea N
    Eur J Heart Fail; 2012 Feb; 14(2):130-7. PubMed ID: 22219501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management.
    Steingart RM; Yadav N; Manrique C; Carver JR; Liu J
    Semin Oncol; 2013 Dec; 40(6):690-708. PubMed ID: 24331191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy-induced cardiomyopathy.
    Higgins AY; O'Halloran TD; Chang JD
    Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eschenhagen T; Force T; Ewer MS; de Keulenaer GW; Suter TM; Anker SD; Avkiran M; de Azambuja E; Balligand JL; Brutsaert DL; Condorelli G; Hansen A; Heymans S; Hill JA; Hirsch E; Hilfiker-Kleiner D; Janssens S; de Jong S; Neubauer G; Pieske B; Ponikowski P; Pirmohamed M; Rauchhaus M; Sawyer D; Sugden PH; Wojta J; Zannad F; Shah AM
    Eur J Heart Fail; 2011 Jan; 13(1):1-10. PubMed ID: 21169385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical cardiac tolerability of trastuzumab.
    Perez EA; Rodeheffer R
    J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected?
    Wells QS; Lenihan DJ
    Prog Cardiovasc Dis; 2010; 53(2):140-8. PubMed ID: 20728701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
    O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced heart failure due to cancer therapy.
    Shah S; Nohria A
    Curr Cardiol Rep; 2015; 17(4):16. PubMed ID: 25687365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac re-synchronization therapy in a child with severe anthracycline-induced congestive heart failure and normal QRS duration.
    Jones BO; Davis AM; Alison J; Weintraub RG; Butt W; Cheung MM
    J Heart Lung Transplant; 2007 Dec; 26(12):1333-5. PubMed ID: 18096487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular toxicities of biological therapies.
    Ryberg M
    Semin Oncol; 2013 Apr; 40(2):168-77. PubMed ID: 23540742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
    Tocchetti CG; Gallucci G; Coppola C; Piscopo G; Cipresso C; Maurea C; Giudice A; Iaffaioli RV; Arra C; Maurea N
    Eur J Heart Fail; 2013 May; 15(5):482-9. PubMed ID: 23325019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.